Literature DB >> 17108759

Impact of hemochromatosis screening in patients with indeterminate results: the hemochromatosis and iron overload screening study.

Roger T Anderson1, Lari Wenzel, Ann P Walker, Andrea Ruggiero, Ronald T Acton, Mark A Hall, Diane C Tucker, Elizabeth Thomson, Barbara Harrison, Edmund Howe, Joan Holup, Catherine Leiendecker-Foster, Tara Power, Paul Adams.   

Abstract

PURPOSE: Assess the quality of life impact of receiving indeterminate test results for hemochromatosis, a disorder involving HFE genetic mutations and/or elevated serum transferrin saturation and ferritin.
METHODS: The study sample was from the Hemochromatosis and Iron Overload Screening Study, a large observational study of hemochromatosis among primary care patients in the US and Canada using HFE genotype and serum transferrin saturation and ferritin screening. Study subjects included 2,304 patients found with hemochromatosis risk of uncertain clinical significance. Assessed was SF-36 general health and emotional well-being before screening and six weeks after participants received their test results. Health worries were assessed after screening.
RESULTS: Of the study subjects, 1,268 participants (51.5%) completed both assessments. Compared to normal controls, those with HFE mutations or elevated serum transferrin saturation and ferritin levels of uncertain significance were more likely to report diminished general health and mental well-being, and more health worries. These effects were associated with participants' belief of having tested positive for hemochromatosis or iron overload.
CONCLUSION: Notification of indeterminate results from screening may be associated with mild negative effects on well-being, and might be a potential participant risk in screening programs for disorders with uncertain genotype-phenotype.

Entities:  

Mesh:

Year:  2006        PMID: 17108759     DOI: 10.1097/01.gim.0000245631.07117.ac

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  6 in total

1.  Effect of ambiguous hemochromatosis gene test results on physician utilization.

Authors:  Mark Speechley; David Alter; Helen Guo; Helen Harrison; Paul C Adams
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

2.  Points to consider in assessing and appraising predictive genetic tests.

Authors:  Wolf H Rogowski; Scott D Grosse; Jürgen John; Helena Kääriäinen; Alastair Kent; Ulf Kristofferson; Jörg Schmidtke
Journal:  J Community Genet       Date:  2010-10-16

3.  A new approach to assessing affect and the emotional implications of personal genomic testing for common disease risk.

Authors:  Suzanne C O'Neill; Kenneth P Tercyak; Chanza Baytop; Sharon Hensley Alford; Colleen M McBride
Journal:  Public Health Genomics       Date:  2015-01-21       Impact factor: 2.000

4.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

5.  Potential nonresponse bias in a clinical examination after initial screening using iron phenotyping and HFE genotyping in the hemochromatosis and iron overload screening study.

Authors:  Mark Speechley; James C Barton; Leah Passmore; Helen Harrison; David M Reboussin; Emily L Harris; Charles A Rivers; Margaret Fadojutimi-Akinsiku; Lari Wenzel; Sharmin Diaz
Journal:  Genet Test Mol Biomarkers       Date:  2009-12

6.  Impact of gene patents and licensing practices on access to genetic testing for hereditary hemochromatosis.

Authors:  Subhashini Chandrasekharan; Emily Pitlick; Christopher Heaney; Robert Cook-Deegan
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.